Drugs / HUMAN C-PEPTIDE

Trials 1 · a red edge is where a trial was stopped

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00278980 Oct 2003 → Dec 2004 diabetic polyneuropathy, type 1 diabetes mellitus Creative Peptides Sweden Inc. Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06470295 Comparator Jun 2024 → Jun 2027 expected hypoglycemia, type 1 diabetes mellitus University of Cincinnati Recruiting No outcome recorded
Phase 11 trial
Phase 1 NCT01665638 Background Sep → Oct 2012 Janssen-Cilag International NV Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as HUMAN C-PEPTIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL4594409
Known as C-peptide ClinicalTrials.gov intervention name — accepted as the source's own label NCT00278980
2

NCT06470295

NCT01665638

Known as Human proinsulin c-peptide ChEMBL registry synonym — accepted as the source's own label CHEMBL4594409
Known as Insulin c-peptide ChEMBL registry synonym — accepted as the source's own label CHEMBL4594409
Known as Nmij-crm 6901a ChEMBL registry synonym — accepted as the source's own label CHEMBL4594409
Known as Proinsulin c-peptide ChEMBL registry synonym — accepted as the source's own label CHEMBL4594409
Known as Proinsulin c-peptide (human) ChEMBL registry synonym — accepted as the source's own label CHEMBL4594409
Modality Peptide “C-peptide administration” NCT00278980
Route Intravenous “administered i.v. (in the vein)” NCT01665638